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Background: Acute exacerbations of COPD (AECOPD) are often associated with infectious agents, some of which
may be non-usual, including Aspergillus spp. However, the importance of Aspergillus spp. in the clinical management
of AECOPD still remains unclear.
Objectives: The aims of the study were to analyze the prevalence and risk factors associated with Aspergillus spp.
isolation in AECOPD, and to investigate the associated clinical outcomes during a 1-year follow-up period.
Methods: Patients presenting with an AECOPD requiring hospitalization were prospectively included from four
hospitals across Spain. Clinical, radiological and microbiological data were collected at admission and during the
follow-up period (1, 6 and 12 months after discharge), and re-admissions and mortality data collected during the
follow-up.
Results: A total of 240 patients with severe AECOPD were included. Valid sputum samples were obtained in 144
(58%) patients, and in this group, the prevalence of Aspergillus spp. isolation was 16.6% on admission and 14.1% at
one-year follow-up. Multivariate logistic-regression showed that AECOPD in the previous year (OR 12.35; 95% CI,
1.9-29.1; p < 0.001), concurrent isolation of pathogenic bacteria (OR 3.64; 95% CI 1.65-9.45, p = 0.001) and
concomitant isolation of Pseudomonas aeruginosa (OR 2.80; 95% IC, 1.81-11.42; p = 0.001) were the main risk
factors for Aspergillus spp. isolation.
Conclusions: The main risk factors for Aspergillus spp. isolation were AECOPD in the previous year and
concomitant isolation of Pseudomonas aeruginosa. However, although Aspergillus spp. is often isolated in
sputum samples from patients with AECOPD, the pathogenic and clinical significance remains unclear.Introduction
Exacerbations of chronic obstructive pulmonary disease
(COPD) are frequent events in the natural history of the
disease, increasing mortality especially when patients re-
quire hospitalization [1,2]. Acute exacerbations of COPD
(AECOPD) are characterized clinically by worsening of
dyspnoea, increased sputum production and/or changes
in sputum purulence [3]. There is evidence suggesting* Correspondence: atorres@clinic.ub.es
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unless otherwise stated.that some infectious agents, typically respiratory viruses
and bacteria, increase bronchial and systemic inflamma-
tion, which is commonly seen in AECOPD [4,5].
Overall, these microbial agents account for the eti-
ology of 75% of AECOPD, particularly in Anthonisen
Type I exacerbations [6]. However, the role of non-usual
microorganisms such as Aspergillus spp. has not been
well established. Previous published data investigating
Aspergillus spp. in COPD are retrospective [7] or were
conducted in a small series of patients [8]. However,
Aspergillus spp. may be responsible for important clin-
ical events from saprophytic colonization of the airways
to rapidly invasive and life-threatening disseminated dis-
eases, depending on the host immune status and theLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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severe COPD who often receive broad-spectrum anti-
biotics and corticosteroids are now acknowledged to
be one of the main risk groups for pulmonary aspergil-
losis [10,11].
As little is known about the risk of pulmonary asper-
gillosis in severe COPD patients, some retrospective
studies have analyzed the incidence of Aspergillus fumigatus
isolation from lower respiratory tract samples in non-
immunocompromised patients and shown that COPD pa-
tients are an important group which are affected by either
colonization or proven aspergillosis [12].
In one of the largest studies investigating the preva-
lence of Aspergillus spp. from Aspergillus respiratory
samples in a cohort of critically ill patients, positive cul-
tures Aspergillus occurred in 36 out of a total of 1756
patients, and Aspergillus treatment with steroids (odds
ratio (OR) = 4.5) and chronic obstructive pulmonary
disease (OR = 2.9) were significantly associated with
Aspergillus spp. isolation in their multivariate analysis
[13]. However, it remains unclear why some COPD pa-
tients are colonized by Aspergillus spp. whereas others
develop invasive pulmonary disease. Colonization may
correspond to a temporary passage of Aspergillus spp. in
the airways, long-term benign carriage, or a sign of pre-
ceding invasive disease [14-17]. However, the absence of
prospective studies designed to determine the prevalence
of Aspergillus spp. airway colonization Aspergillusin pa-
tients with AECOPD means that it has not been possible
to define the influence of this organism as a causal agent
of exacerbations.
Thus, the aim of this study was to analyze the preva-
lence, risk factors and clinical evolution associated with
the respiratory isolation of Aspergillus spp. in a cohort
of COPD patients requiring admission to the hospital
with an AECOPD.
Methods
Study data and design
Data was prospectively collected from patients hospital-
ized due to a severe COPD exacerbation in four tertiary
university teaching hospitals in Spain between January
2008 and December 2009. Ethics Approval Committee
(CEIC 2008/4325) and all patients provided written in-
formed consent.
Definitions
A complete definition of COPD, severe COPD exacerba-
tion and pulmonary Aspergillus spp. infection.
Study protocol
Only COPD patients with GOLD confirmed by spirom-
etry were included. Patients were evaluated for inclusion
in the study within the first 24 hours after admission tothe Emergency Department. Diagnosis of COPD exacer-
bation, decision to hospitalize, time of discharge and
choice of pharmacological therapy were taken by the
physician in charge. Patients with active tuberculosis,
asthma, immunosuppression (innate or acquired) or any
other clinical respiratory diseases were excluded. All pa-
tients discharged after an AECOPD were scheduled for
follow-up visits at one, six and 12 months. Each patient
was only included once in the analysis, despite the possi-
bility of more than one re-admission during the follow-
up period.Data collection
Demographic variables, presence of any comorbid condi-
tions (heart, renal, neurologic and liver disease, diabetes
or cancer), smoking status, perceived dyspnoea and use of
pharmacotherapy (including COPD baseline treatment, an-
tibiotics, and anti-pneumococcal and/or flu vaccination)
were recorded on admission to hospital. Symptoms/signs of
the AECOPD together with physiological and laboratory
data were collected at onset. Other variables such as length
of stay (LOS), frequency of patients in whom admission to
the intensive care unit (ICU) was needed, or requirement
of non-invasive mechanical ventilation (NIMV) were also
recorded.
The number of AECOPD events in the year preceding
hospitalization was assessed based on recorded data and
a search of the database of all hospital contacts. Only ex-
acerbations requiring emergency room visits or admis-
sions were included.Microbiological analysis
Spontaneous sputum samples were obtained on admis-
sion and in each follow-up visit where possible. Sputum
was examined for leukocytes and epithelial cells by gram
stain, and samples with a Murray-Washington classifica-
tion criteria IV (10-25 epithelial cells and >25 leukocytes
per field) or V (≤10 epithelial cells and >25 leukocytes
per field) were considered representative of distal air-
ways and subsequently processed for culture. Bacterial
growth was assessed at 48 hours and fungal growth after
72 hours. The airway bacteria cultured were classified
into potential pathogenic microorganisms (PPMs) and
non-PPMs, as previously described [5]. Samples were
processed by the reference clinical microbiology labora-
tories of the participating hospitals using standard pro-
cedures, including Sabouraud agar culture, for the
isolation of fungal species. Cultures were incubated at
32°C-37°C for at least 7 days and the number of visible
colonies recorded. After seven days, filamentous colonies
were examined and Aspergillus spp. identified based on
macroscopic and microscopic methods.
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Data were analysed using SPSS version 17.0 for Windows
(SPSS Inc., Chicago, IL, USA). Categorical variables are pre-
sented as absolute numbers and relative frequencies, while
continuous variables are presented as the mean, standard
deviation (SD) in parametric data, or median with the inter-
quartile (IQR) range in non-parametric data. Categorical
variables were compared using the χ2 test or Fisher’s exact
test, as appropriate. For the comparison of continuous vari-
ables, the t test was used if normality was demonstrated;
otherwise, the non-parametric Mann-Whitney U test was
performed.
In order to determine the risk factors associated with the
presence of Aspergillus spp. in the airways, we used both
univariate and multivariate logistic regression model, where
the dependent variable was the isolation of Aspergillus spp.
in patients at admission, and independent variables wereFigure 1 Flow diagram of patient inclusion.those associated with demographics and clinical fac-
tors. The association between follow-up visits was ana-
lyzed using the Wilcoxon test for quantitative variables
and McNemar test for dichotomous discrete variables.
We checked the assumptions of normality necessary to
use parametric tests. All tests were two-tailed and
significance was set at 5%. Bonferrioni correction was
used when needed.Results
A total of 307 possible eligible patients presenting to
the emergency department with a severe exacerbation of
COPD were evaluated. Of these, 62 patients presented with
one or more exclusion criteria (Figure 1). In the remaining
245 cases, an alternative diagnose was recorded at discharge
in 5 patients (2%) and they were excluded from the analysis.
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prised of 240 patients.Baseline and clinical characteristics
The cohort recruited consisted predominantly of men
(217 [90%]; mean ± SD age 74.4 ± 8.8 years) and current
smokers (172 [72.6%]). The patients had evidence of
severe airway obstruction (mean FEV1 of 44.0 ± 14.6%
predicted). Previous history of COPD exacerbations was
very common, with 64.2% of patients having had at least
one severe exacerbation in the year preceding the index
hospitalization (mean 2.88 ± 2.27, maximum 6 exacerba-
tions), and among this group, 39% were re-admitted to
the hospital.
Of all the patients included, 170 (70.8%) had previously
received pharmacological treatment for their COPD with a
fixed combination of long acting β2−agonists (LABA) and
inhaled corticosteroids (ICS): formoterol plus budesonide
in 52 patients (30.6%) and fluticasone plus salmeterol in
118 patients (69.4%). 174 (72.5%) patients had receivedTable 1 Characteristics of the study population on admission
All patients
(n = 240)
Age, years 74.4 ± 8.8
Gender, males 217 (90.4)
Past-smoker 175 (72.6)
Current smoker 65 (27.4)
FEV1% predicted 2.6 (1-3)
FVC% predicted 44.0 ± 14.6
Charlson index 69.6 ± 19.6
GOLD stage II 12 (5,8)
GOLD stage III 92 (38,3)
GOLD stage IV 136 (56,1)
COPD exacerbation in the previous year
≤ 2 exacerbations 82 (53.2)
>2 exacerbations 72 (46.7)
Admission for COPD in the previous year 2.6 ± 1.9
Long Term Oxygen Therapy 72 (30.0)
Cardiovascular disease1 131 (54.6)
Arterial hypertension2 112 (46.7)
Diabetes mellitus 65 (27.1)
Chronic renal disease 34 (14.2)
Inhaled corticosteroids 170 (70.8)
<500 mcg daily 106 (62.3)
>500 mcg daily 64 (37.6)
Oral corticosteroids 80 (33.3)
Data are presented as means ± SD, medians (Interquartile range) or absolute numb
hypertension; 2Patients with arterial hypertension without any other cardiovascular
refers only to the comparison between non-aspergillus and Aspergillus isolated populatiothe influenza vaccine and 101 (42.1%) had received the
pneumococcal vaccine.
Analysis of bacterial colonization in the previous year
showed that 85 patients (35.4%) had microbiological
evidence of bacterial colonization in the year prior to in-
clusion. The clinical characteristics of the overall popula-
tion included patients by Aspergillus spp. isolation is
shown in Table 1. There was no significant difference in
clinical characteristics between the two groups (Aspergil-
lus spp. isolation versus no Aspergillus spp. isolation).
The clinical, physiological and laboratory features of the
AECOPD on admission and the subsequent outcomes of
the patients are shown in Table 2.
Microbiological findings and prevalence of Aspergillus
isolation
Sputum of sufficient quality for bacterial and fungal
culture was obtained from 144 patients on admission.
During the initial admission and the subsequent follow-
up visits, a total of 198 sputum samples were collected.
Non-PPMs were isolated in 112 (57%), whilst PPMsbased on Aspergillus spp. isolation
No Aspergillus spp.
isolation (n = 120)#
Aspergillus spp.
isolation (n = 24)#
p-value†
74.2 ± 10.1 73.1 ± 8.2 0.569
103 (85.8) 23 (95.8) 0.246
87(72.5) 18 (75.0) 0.608
33 (27.5) 6 (25.0) 0.779
47.3 ± 12.9 45.4 ± 14.7 0.196
71.9 ± 14.4 68.8 ± 16.4 0.094
2.1 (1.3-3.4) 2.7 (1.6-3.9) 0.060
8 (6.6) - -
46 (38.3) 8 (33.3) 0.436
66 (55.5) 16 (66.6) 0.062
65 (63.7) 7 (38.8) 0.150
37 (36.3) 11 (61.1) 0.050
2.1 ± 0.8 2.4 ± 1.2 0.079
36 (29.1) 9 (37.5) 0.067
61 (50.8) 12 (50.0) 0.475
52 (43.3) 19 (79.2) 0.002
31 (25.8) 9 (37.5) 0.206
15 (12.5) 6 (25.0) 0.052
85 (70.8) 18 (75.0) 0.763
54 (43.5) 12 (66.6) 0.096
31 (36.5) 6 (33.3) 0.267
39 (32.5) 9 (37.5) 0.284
ers (%), as appropriate. 1Patients with cardiovascular disease other than arterial
condition. #Data calculated from the total number of respiratory samples. † p-value
ns.
Table 2 Clinical characteristics of AECOPD at admission and outcomes
All patients No Aspergillus spp. isolation Aspergillus spp.isolation p-value †
(n = 240) (n = 120)# (n = 24)#
Heart rate, beats/min 96.8 ± 16.1 94.7 ± 14.8 95.6 ± 13.4 0.624
Respiratory rate, breath/min 23.3 ± 8.9 22.4 ± 9.7 24.7 ± 7.6 0.286
Body temperature, °C 36.7 ± 0.9 36.4 ± 0.8 36.8 ± 0.9 0.574
Type of exacerbation£
Type I 110 (45.8) 56 (46.6) 10 (41.6) 0.340
Type II 59 (24.3) 30 (25.0) 5 (20.8) 0.127
Type III 81 (33.4) 34 (28.3) 9 (37.5) 0.193
Laboratory findings
Leucocytes, x 109/L 11.8 ± 6.3 11.2 ± 5.9 12.0 ± 4.3 0.391
C-reactive protein, mg/dL 3.2 (1.2-12.3) 2.9 (1.2-13.5) 3.4 (1.6-9-4) 0.192
pH 7.376 ± 0.064 7.401 ± 0.035 7.363 ± 0.078 0.286
PaO2, mmHg 63.1 ± 22.7 64.6 ± 15.7 61.5 ± 17.9 0.141
PaCO2, mmHg 47.8 ± 13.3 45.5 ± 12.8 49.4 ± 17.2 0.096
MV§ requirements on admission 9 (3.7) 8 (6.6) 1 (4.2) 0.297
Length of stay, days 9.6 ± 6.4 7.5 ± 5.0 11.8 ± 9.2 0.025
30-days follow-up
Exacerbations, n 58 (24.1) 29 (24.1) 6 (25.0) 0.540
Hospital re-admissions 34 (14.1) 17 (14.2) 3 (12.5) 0.345
Death by any cause 11 (4.6) 6 (5.0) 1 (4.2) 0.478
12-month follow-up
Exacerbations 131 (54.5) 72 (60.0) 12 (54.4) 0.299
Hospital re-admissions 93 (38.7) 52 (43.3) 7 (31.8) 0.087
ICU admissions 14 (5.8) 8 (6.6) 2 (9.0) 0.065
Death by any cause 27 (11.3) 13 (10.8) 3 (12.5) 0.373
Data are presented as means ± SD, medians (1st quartile; 3rd quartile) or numbers (%) as appropriate. #Data calculated from the number of valid samples.
£Anthonisen exacerbation criteria [4]; £MV, Mechanical ventilation. † p-value refers only to the comparison between non-aspergillus and Aspergillus
isolated populations.
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the most frequently isolated PPM (27%). The full distri-
bution of PPMs is shown in Table 3. 28 (14%) out of the
198 sputum samples had Aspergillus spp. isolated from
24 COPD patients. Only four patients, had Aspergillus
spp. isolated in two different samples during the follow-
up period. Aspergillus fumigatus was isolated in 25 cases,
Aspergillus niger in two, and Aspergillus flavus in one.
The prevalence of Aspergillus spp. isolation in this co-
hort of COPD patients was 16.6% on admission and
14.1% at the end of the follow-up period.
Due to clinical concern that doubtful pulmonary infil-
trates seen on chest X-ray at admission may represent
possible invasive pulmonary aspergillosis (IPA), accord-
ing to Bulpas’s criteria (16), a high resolution computed
thoracic (HRCT) scan was performed in 18 of the 24
patients (75%) with Aspergillus isolation. No features
of IPA were observed in any patient. Nevertheless, in
five patients, their treating physicians decided to startantifungal treatment due to previous exposure to oral
corticosteroids (voriconazole in three cases and itracona-
zole in two).
Risk factors for Aspergillus isolation
Previous bacterial colonization, the number of previous
COPD exacerbations that required hospital visits (emer-
gency room visit or admission) and the presence of ar-
terial hypertension were significantly more frequent in
patients with Aspergillus spp. isolation. Patients with
Aspergillus spp. isolation in their sputum samples, had ex-
perienced more than two previous episodes of AECOPD
compared to those patients without Aspergillus spp. isola-
tion (61 versus 11, p = 0.05).
Analysis of the microbiological data in the overall
population prior to admission, showed a significant asso-
ciation between previous bacterial colonization and the
isolation of Aspergillus spp. (42 versus 11, p = 0.002).
Similarly, there was a significant association between the
Table 3 Cumulative identification and incidence of potential pathogenic microorganisms (PPM) cultured from COPD
patients£
No Aspergillus spp. isolation Aspergillus spp. isolation Total p-value
Sputum samples 170 28 198
Samples with PPM§ cultures 66 (38.8) 20 (71.4) 86 (43) 0.024
Haemophilus influenzae 13 (7.6) 5 (17.8) 18 (9.1) 0.246
Streptococcus pneumoniae 11 (6.4) 2 (7,1) 13 (6.6) 0.626
Staphylococcus aureus 9 (5.3) 3 (10.7) 12 (6.1) 0.372
Moraxella catarrhalis 9 (5.3) 1 (3.6) 9 (5.1) 0.564
Enterobacter spp. 3 (1.8) 1 (3.6) 4 (2.0) 0.632
Klebsiella pneumoniae 2 (1.2) - 2 (1.1) -
Escherichia coli 4 (2.3) - 4 (2.0) -
Serratia marcescens 2 (1.2) - 2 (1.1) -
Pseudomonas aeruginosa 14 (8.2) 9 (32.1) 23 (11.6) 0.042
Stenotrophomonas maltophilia 2 (1.1) - 2 (1.1) -
Aspergillus fumigatus - 25 (89.3) 25 (12.6) -
Aspergillus spp.* - 3 (10.7) 3 (1.5) -
Samples with non-PPM# cultures 104 (61.2) 8 (28.6) 112 (56.6) 0.063
Haemophilus parainfluenzae 14 (8.2) 2 (7.1) 16 (8.1) 0.674
Streptococcus viridans 41 (24.1) 2 (7.1) 43 (21.7) 0.135
Staphylococcus epidermidis 14 (8.2) - 14 (7.1) -
Corynebacterium spp. 8 (4.7) - 8 (4.0) -
Neisseria spp. 6 (3.5) - 6 (3.0) -
Mixed upper airways flora 21 (12.3) 4 (14.3) 25 (12.6) 0.78
£All comparisons have been calculated in valid sputum samples obtained in each group. *Aspergillus spp.: Aspergillus niger (2), Aspergillus flavus (1); §PPM,
Pathogenic microorganisms; #non-PPM, Non-pathogenic microorganisms.
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the study period and concurrent isolation of Aspergillus
spp compared to those patients without PPMs but with
Aspergillus spp. isolation (66 versus 20, p = 0.02). This dif-
ference was also significant in cases with previous isolation




Arterial hypertension 6.48 1.17-35.84
Cardio vascular disease 9.97 1.30-76.47
Diabetes mellitus 3.52 1.77-15.94
Chronic renal disease 2.92 2.23-15.35
COPD exacerbation in the previous year § 2.60 1.16-6.11
Previous bacterial colonization 3.50 1.47-8.37
Concurrent PPM isolation £ 2.92 1.42-6.84
Concurrent P. aeruginosa isolation 2.10 1.21-5.68
§COPD exacerbation that required hospital management (emergency room visit or
£PPM, Pathogenic microorganisms.Table 4 summarizes the results of the multivariate ana-
lysis of risk factors potentially associated with Aspergillus
spp. isolation. Significant variables associated independently
with Aspergillus spp. isolation were arterial hypertension
(OR 4.72; 95% confidential interval (CI), 1.56-14.29; p <
0.001), COPD exacerbation that required hospitalization insion analysis for the prediction of Aspergillus spp. risk
nalysis Multivariate analysis
p-value OR 95%CI p-value
0.032 4.72 1.56-14.39 0.001
0.027 - - -
0.041 - - -
0.070 - - -
0.050 12.35 1.87-29.14 <0.001
0.002 - - -
0.024 3.64 1.65-9.45 0.001
0.042 2.80 1.81-11.42 0.001
admission).
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concurrent PPMs isolation (OR 3.64; 95% CI, 1.65-9.45;
p = 0.001), and concomitant isolation on the same sample
of Pseudomonas aeruginosa (OR 2.80; 95% CI, 1.81-11.42;
p = 0.001).
Short-term and long-term clinical outcomes
The short- and long-term clinical outcomes are shown
in Table 2. Patients with Aspergillus spp. isolation had
significantly higher LOS compared to those patients
without Aspergillus spp. isolation (7.5 ± 5.0 days Aspergillus
versus 11.8 ± 9.2 days Aspergillus, p = 0.02). No differences
were found in the rate of exacerbations within the first
month (24% versus 25%; p = 0.54) or during the follow-up
(60% versus 54%; p = 0.34).
The overall mortality rate at 12 months was 11.3% (27
patients); 13 (10.8%) in the non-Aspergillus spp. group and
three (12.5%) in the Aspergillus spp. group (p = 0.373).
Discussion
This is the first study to date to prospectively determine
the prevalence of airway Aspergillus spp. and examine
the associated risk factors for isolation, in a cohort of
severe COPD patients requiring hospitalization for an
AECOPD. We have shown that the prevalence of Aspergil-
lus spp. isolation in this cohort was 16.6% on admission
and 14.4% at the end of one-year follow-up. The independ-
ent risk factors associated with Aspergillus spp. colonization
were an AECOPD in the previous year, and the concurrent
isolation of PPMs, most frequently Pseudomonas aerugi-
nosa. Notably, Aspergillus spp. isolation was not associated
with more severe exacerbations or worse clinical outcomes
after a one-year follow up.
We found 28 Aspergillus spp. isolates using a standard
method for mycological investigations in spontaneous spu-
tum samples. The prevalence rate of 14.4% in our COPD
cohort after a one-year follow-up was surprisingly high. In
fact, Aspergillus spp. was the most frequent microorgan-
isms isolated, together with Pseudomonas aeruginosa.
Importantly, we found significant differences in the bacter-
ial pathogens isolated in the patients with and without
Aspergillus spp. isolation, independent of COPD severity,
suggesting an increase in the rate of co-infection in COPD
patients who present with Aspergillus spp. isolation.
The prevalence of Aspergillus spp. isolation may have
been higher if we had used bronchoscopic techniques
and specific culture media. However, in real-life settings,
clinicians often only have access to sputum samples. In a
recent study, Phasley et al. [18] reported that the isola-
tion of Aspergillus fumigatus in sputum culture was
significantly higher using a research approach compared
to the standard method for mycological investigations.
Previous studies, which have not focused solely on
Aspergillus spp., have found different prevalence rates offungi isolation in respiratory samples from patients with
cystic fibrosis, COPD and asthma [19-21]. Recently, a
large, retrospective study conducted by Guinea et al. [7],
analyzed the incidence of Aspergillus fumigatus isolation
from lower respiratory tract samples in patients admit-
ted for AECOPD in a tertiary hospital The authors
found 239 isolations of Aspergillus spp. (16.3 per 1000
admissions), but only 53 (22%) patients had probable
IPA. However, unlike our prospective study, the fungal
isolations were detected retrospectively by the micro-
biology laboratory.
There is no doubt that COPD patients are a population
at risk for Aspergillus spp. colonization [12,14]. In a previ-
ous study of critically ill patients, Aspergillus spp. isolation
from respiratory secretions was significantly associated with
both an underlying diagnosis of COPD and treatment with
corticosteroids [13]. These findings have been confirmed by
other authors, and have strengthened the relationship be-
tween pulmonary infection with Aspergillus spp. and the
use of intravenous corticosteroids in COPD patients admit-
ted to the ICU for severe exacerbation [16]. In contrast, a
study conducted by Afessa et al. [22] reported no isolation
of Aspergillus spp. in the respiratory specimens from 250
COPD patients admitted to the ICU because of acute re-
spiratory failure, although no report on corticosteroid ther-
apy was performed.
The concurrent isolation of other pathogens, especially
Pseudomonas aeruginosa was also associated with a higher
risk of Aspergillus spp. isolation. Although the role of bac-
terial infection in COPD exacerbations remains controver-
sial, Pseudomonas aeruginosa is usually isolated in patients
with advanced COPD stages [23-25]. In addition, the inci-
dence of Pseudomonas aeruginosa in sputum samples from
patients hospitalized with COPD exacerbations is high, and
its isolation could also be a marker of poor prognosis inde-
pendently of other predictors [26].
Patients with previous severe exacerbations are more
likely to receive a higher number of antibiotic therapy
courses, and this could be the key factor in promoting
further Aspergillus spp. isolation. In fact, in a recent
publication, it was found that almost 73% of COPD pa-
tients in Spain presenting with a Type I Anthonisen ex-
acerbation received antibiotics [27]. Prospective studies
focusing on this specific population are much needed to
determine whether Aspergillus spp. isolation is the cause
or the consequence of more infectious exacerbations
with concurrent isolation of Pseudomonas aeruginosa.
Paradoxically to the data of Bafhadel et al. [28], we
found no association between the use of either inhaled
(ICS) or oral (OCS) corticosteroids and an increased rate
of Aspergillus spp.
Colonization of the distal airways by filamentous fungi,
such as Aspergillus spp., can occur during the course of
COPD, although the clinical relevance is unclear. To
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spp. contributes to the increased frequency and severity
of exacerbations, or is a marker of more severe disease.
In our study, except for a longer LOS, we found no sig-
nificant differences in any of the other clinical outcomes
when comparing patients with and without Aspergillus
spp. isolation. Therefore, antifungal treatment may not
be beneficial in these patients. Only five of our patients
were treated with antifungals despite the fact that none
of the CT scans performed showed radiological signs of
pulmonary aspergillosis but only doubtful infiltrates on
chest x-ray at admission. Importantly, we followed up
patients for one year, and there was no significant differ-
ence in ICU-admissions and hospital readmissions be-
tween the non-Aspergillus and Aspergillus spp. isolation
groups, again suggesting that Aspergillus spp. detection
does not worsen clinical outcomes.
Several limitations of our study require attention. Firstly,
we only used sputum samples for culture, and it can be ar-
gued that the value of these specimens is poor in identifying
the etiologic agent of the exacerbation. Obtaining sputum
samples is a real-life cost-effective tool, but may have lim-
ited value in distinguishing transitional Aspergillus spp. iso-
lation from chronic colonization. However, in a previous
bronchoscopic validation study published by our group, we
found a high concordance between fungal pathogens in
samples retrieved via protected specimen brush and
sputum (κ = 0.85, p < 0.002) [29]. Although there are new
microbiological techniques for the rapid detection of
Aspergillus spp. that provide results in less than 4 hours
(compared to 3 or more days using conventional culture)
[30], until they become widely available, conventional spu-
tum culture remains a good diagnostic tool for Aspergillus
spp. identification. Secondly, this study was performed in
patients admitted with a severe AECOPD in Spain, and
bacteria and fungi flora may differ in different countries.
Thirdly, we did not routinely perform CT scans on admis-
sion to all patients with Aspergillus spp. isolation. However,
none of the 18 patients who were evaluated by a CT scan
showed any radiological signs of invasive or chronic pul-
monary aspergillosis. Finally, we did not investigate plasma
galactomannan antigen, and are unaware of the value of
this pathogenic marker in severe COPD patients with
Aspergillus spp. isolation. In a recent study of critically ill
patients, bronchoalveolar lavage (BALF) galactomannan
had a higher sensitivity in the early diagnosis of IPA but its
value still remains unclear since the collection and process-
ing of BALF samples for Aspergillus spp. has not yet been
standardized [31]. In another study, the cut-off of value for
Platelia galactomannan of 1 ng/ml was the best for diagnos-
ing invasive aspergillosis, with both high sensitivity and
specificity [32].
In summary, we found a high prevalence of Aspergillus
spp. isolation in a cohort of COPD patients with severeAECOPD requiring hospitalization. Except for a longer
LOS, we found no differences in the short-term or long-
term outcomes. We detected clinical and microbiological
risk factors for Aspergillus isolation. However, the infect-
ive role of these isolates seems to be minimal. Our find-
ings may serve to propose future more comprehensive
studies, with a biological basis that includes pulmonary
and systemic markers of the immune and inflammatory
response, in order to determine the role of this fungus
in COPD exacerbations.
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